U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07422051) titled 'Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis' on Feb. 10.
Brief Summary: The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are:
Is erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages?
Researc...